226 related articles for article (PubMed ID: 31710995)
21. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
[TBL] [Abstract][Full Text] [Related]
22. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
Santos FM; Marin JFG; Lima MS; Silva-Junior WF; Alves LBO; Moreira FR; Velasques RD; Atanazio MJ; Maia ACA; Buchpiguel CA; Buccheri V; Rocha V
Ann Hematol; 2024 Jan; 103(1):175-183. PubMed ID: 37796339
[TBL] [Abstract][Full Text] [Related]
23. Prognostic nomogram for diffuse large B-cell lymphoma incorporating the International Prognostic Index with interim-positron emission tomography findings.
Chow A; Phillips M; Siew T; Cull G; Augustson B; Ward M; Joske D
Intern Med J; 2013 Aug; 43(8):932-9. PubMed ID: 23692386
[TBL] [Abstract][Full Text] [Related]
24. Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.
Girum KB; Cottereau AS; Vercellino L; Rebaud L; Clerc J; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2024 Feb; 65(2):313-319. PubMed ID: 38071535
[TBL] [Abstract][Full Text] [Related]
25. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
[TBL] [Abstract][Full Text] [Related]
26. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
27. Serum level of soluble interleukin-2 receptor is positively correlated with metabolic tumor volume on
Senjo H; Kanaya M; Izumiyama K; Minauchi K; Hirata K; Mori A; Saito M; Tanaka M; Iijima H; Tsukamoto E; Itoh K; Ota S; Morioka M; Hashimoto D; Teshima T;
Cancer Med; 2019 Mar; 8(3):953-962. PubMed ID: 30790452
[TBL] [Abstract][Full Text] [Related]
28. Improved prediction of chemoresistance in patients with diffuse large B-cell lymphoma through a new interim positron emission tomography-computed tomography evaluation model.
Xie W; Liu MK; Jiang XF; Gao XD; Li B; Wang L; Zhao WL
Acta Oncol; 2021 Jun; 60(6):735-743. PubMed ID: 33720799
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of the metabolic bulk volume in patients with diffuse large B-cell lymphoma on baseline
Delaby G; Hubaut MA; Morschhauser F; Besson A; Huglo D; Herbaux C; Baillet C
Leuk Lymphoma; 2020 Jul; 61(7):1584-1591. PubMed ID: 32100597
[TBL] [Abstract][Full Text] [Related]
30. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
[TBL] [Abstract][Full Text] [Related]
31. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
32. Deep-Learning
Capobianco N; Meignan M; Cottereau AS; Vercellino L; Sibille L; Spottiswoode B; Zuehlsdorff S; Casasnovas O; Thieblemont C; Buvat I
J Nucl Med; 2021 Jan; 62(1):30-36. PubMed ID: 32532925
[TBL] [Abstract][Full Text] [Related]
33. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.
Sasanelli M; Meignan M; Haioun C; Berriolo-Riedinger A; Casasnovas RO; Biggi A; Gallamini A; Siegel BA; Cashen AF; Véra P; Tilly H; Versari A; Itti E
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2017-22. PubMed ID: 24902639
[TBL] [Abstract][Full Text] [Related]
34. Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment
Györke T; Carr R; Cerci JJ; Meneghetti C; Redondo F; Celli M; Gorospe C; Auewarakul CU; Jorgov L; Paez D; Fanti S
J Nucl Med; 2020 Jul; 61(7):999-1005. PubMed ID: 31757842
[TBL] [Abstract][Full Text] [Related]
35. Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?
Le Gouill S; Casasnovas RO
Blood; 2017 Jun; 129(23):3059-3070. PubMed ID: 28416502
[No Abstract] [Full Text] [Related]
36. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [
Zhang X; Chen L; Jiang H; He X; Feng L; Ni M; Ma M; Wang J; Zhang T; Wu S; Zhou R; Jin C; Zhang K; Qian W; Chen Z; Zhuo C; Zhang H; Tian M
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1298-1310. PubMed ID: 34651227
[TBL] [Abstract][Full Text] [Related]
37. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
38. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index.
Yim SK; Yhim HY; Han YH; Jeon SY; Lee NR; Song EK; Jeong HJ; Kim HS; Kwak JY
Ann Hematol; 2019 Dec; 98(12):2739-2748. PubMed ID: 31712879
[TBL] [Abstract][Full Text] [Related]
39. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis.
Guo B; Tan X; Ke Q; Cen H
PLoS One; 2019; 14(1):e0210224. PubMed ID: 30625203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
